Trends in incidence of anal cancer in Austria, 1983-2016.
Anal cancer
Austria
Incidence
Screening
Time trend
Journal
Wiener klinische Wochenschrift
ISSN: 1613-7671
Titre abrégé: Wien Klin Wochenschr
Pays: Austria
ID NLM: 21620870R
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
18
12
2019
accepted:
10
02
2020
pubmed:
5
3
2020
medline:
18
11
2020
entrez:
5
3
2020
Statut:
ppublish
Résumé
Recent reports have noted increasing rates of anal cancer among high-income countries worldwide; however, little is known about these trends in Austria. Data on anal cancer from 1983 to 2016 were obtained from Statistics Austria. All tumors (n = 3567) were classified into anal squamous cell carcinomas (ASCC), anal adenocarcinomas (AADC), and others (unspecified carcinoma and other specific carcinoma). Anal cancer incidence rates were calculated in 5‑year cycles and incidence average annual percentage change (AAPC) to evaluate trends by sex, histology and age group. The incidence rate of anal cancer was higher among females than males (relative risk, RR = 1.66, 95% confidence interval, CI: 1.55-1.79, p < 0.0001). From 1983 through 2016, incident anal cancer increased significantly (0.92 per 100,000 person-years to 1.85 per 100,000 person-years, AAPC = 1.93, 95% CI: 1.52 to 2.34, p < 0.0001), particularly among those 40-69 years old. From 1983 through 2016, the increasing anal cancer incidence was primarily driven by ASCC (0.47-1.20 per 100,000 person-years, AAPC = 2.23, 95% CI: 1.58 to 2.88, p < 0.0001) and others (other than ASCC and AADC, AAPC = 1.78, 95% CI: 1.01-2.55), yet stable in AADC (AAPC = 0.88, 95% CI: -0.48-2.25). Despite being a rare cancer in Austria, the increase in anal cancer incidence rate from 1983 to 2016 was substantial, particularly in ASCC. The observed rising trends reflect the need to investigate associated risk factors that have increased over time to inform preventive measures.
Sections du résumé
BACKGROUND
BACKGROUND
Recent reports have noted increasing rates of anal cancer among high-income countries worldwide; however, little is known about these trends in Austria.
METHODS
METHODS
Data on anal cancer from 1983 to 2016 were obtained from Statistics Austria. All tumors (n = 3567) were classified into anal squamous cell carcinomas (ASCC), anal adenocarcinomas (AADC), and others (unspecified carcinoma and other specific carcinoma). Anal cancer incidence rates were calculated in 5‑year cycles and incidence average annual percentage change (AAPC) to evaluate trends by sex, histology and age group.
RESULTS
RESULTS
The incidence rate of anal cancer was higher among females than males (relative risk, RR = 1.66, 95% confidence interval, CI: 1.55-1.79, p < 0.0001). From 1983 through 2016, incident anal cancer increased significantly (0.92 per 100,000 person-years to 1.85 per 100,000 person-years, AAPC = 1.93, 95% CI: 1.52 to 2.34, p < 0.0001), particularly among those 40-69 years old. From 1983 through 2016, the increasing anal cancer incidence was primarily driven by ASCC (0.47-1.20 per 100,000 person-years, AAPC = 2.23, 95% CI: 1.58 to 2.88, p < 0.0001) and others (other than ASCC and AADC, AAPC = 1.78, 95% CI: 1.01-2.55), yet stable in AADC (AAPC = 0.88, 95% CI: -0.48-2.25).
CONCLUSIONS
CONCLUSIONS
Despite being a rare cancer in Austria, the increase in anal cancer incidence rate from 1983 to 2016 was substantial, particularly in ASCC. The observed rising trends reflect the need to investigate associated risk factors that have increased over time to inform preventive measures.
Identifiants
pubmed: 32130523
doi: 10.1007/s00508-020-01622-z
pii: 10.1007/s00508-020-01622-z
pmc: PMC7445201
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
438-443Références
Lancet Glob Health. 2016 Sep;4(9):e609-16
pubmed: 27470177
Int J Epidemiol. 2017 Jun 1;46(3):924-938
pubmed: 27789668
Cancer. 2004 Jul 15;101(2):270-80
pubmed: 15241823
MMWR Morb Mortal Wkly Rep. 2011 Dec 23;60(50):1705-8
pubmed: 22189893
Br J Cancer. 2006 Jul 3;95(1):87-90
pubmed: 16721368
Lancet Infect Dis. 2018 Feb;18(2):198-206
pubmed: 29158102
Surg Oncol Clin N Am. 2017 Jan;26(1):9-15
pubmed: 27889039
Clin Infect Dis. 2012 Apr;54(7):1026-34
pubmed: 22291097
Eur J Cancer Prev. 2016 May;25(3):182-7
pubmed: 25973771
Lancet Infect Dis. 2019 Aug;19(8):880-891
pubmed: 31204304
Lancet Oncol. 2004 Mar;5(3):149-57
pubmed: 15003197
Curr Infect Dis Rep. 2005 May;7(3):227-234
pubmed: 15847726
Lancet Infect Dis. 2019 Aug;19(8):799-800
pubmed: 31204305
Br J Cancer. 2009 Feb 10;100(3):527-31
pubmed: 19156144
Eur J Oncol Nurs. 2015 Oct;19(5):479-85
pubmed: 25911268
Clin Infect Dis. 2016 Dec 15;63(12):1668-1676
pubmed: 27609756
PLoS One. 2018 Oct 19;13(10):e0205105
pubmed: 30339668
N Engl J Med. 2011 Oct 27;365(17):1576-85
pubmed: 22029979
Cancer Epidemiol. 2015 Dec;39(6):842-7
pubmed: 26651444
Lancet. 2017 May 13;389(10082):1885-1906
pubmed: 28390697
Oncologist. 2016 Apr;21(4):453-60
pubmed: 26961923
Cancer Epidemiol Biomarkers Prev. 2020 Jan;29(1):185-192
pubmed: 31597665
Arch Sex Behav. 2015 Nov;44(8):2273-85
pubmed: 25940736
Am J Prev Med. 2011 Apr;40(4):427-33
pubmed: 21406276
Int J Cancer. 2012 Mar 1;130(5):1168-73
pubmed: 21469144
Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10):1548-56
pubmed: 26224796
AIDS. 2010 Feb 20;24(4):535-43
pubmed: 19926961